Psilocybin-assisted therapy and depression - a systematic review

Detalhes bibliográficos
Autor(a) principal: Rui Pedro Leal Andrade
Data de Publicação: 2020
Tipo de documento: Dissertação
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://hdl.handle.net/10216/128706
Resumo: Background: Psilocybin is a naturally occurring serotonin receptor agonist that can be, more commonly, found in the Psilocybe mushrooms. Consumed by indigenous cultures for millenia, Psilocybin, in the 1960s, was marketed in many countries under the trade name Indocybin, and, before its eventual ban, was safely used as an adjunct to psychotherapy in the treatment of depression and anxiety. Recently, the safety and ease of practical use of psilocybin propelled its resurrection and positive preliminary reports on the safety and tolerability of psilocybin for multiples diseases, such as obsessive-compulsive disorder and addiction, have been published. Aims: The main objective of this review is to outline existing scientific information about the effects of Psilocybin-based therapy on patients diagnosed with depression. Methods: Using PubMed as the database, a research was conducted, based on the research words *Psilocybin and *Depression and targeting clinical trials. References of selected articles and review articles were also assessed. Results: A total of 4 articles met the inclusion criteria. 2 articles evaluate psilocybin effects in 32 patients with treatment-resistant depression. The remaining 2 articles evaluate psilocybin effects in 80 patients with cancer-related anxiety and depression. All articles showed that psilocybin produced immediate and substantial improvements in depression, that, ultimately, could sustain up to 6 months. Conclusion: Psilocybin-assisted therapy is a very appealing new possibility in the treatment of depression. However, due to the small populations of the existing trials, future studies are needed to prove this positive association and to fully understand Psilocybin´s mechanisms of action and effects.
id RCAP_20c5e921bc98ed95f586ce283fa2a490
oai_identifier_str oai:repositorio-aberto.up.pt:10216/128706
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Psilocybin-assisted therapy and depression - a systematic reviewMedicina clínicaClinical medicineBackground: Psilocybin is a naturally occurring serotonin receptor agonist that can be, more commonly, found in the Psilocybe mushrooms. Consumed by indigenous cultures for millenia, Psilocybin, in the 1960s, was marketed in many countries under the trade name Indocybin, and, before its eventual ban, was safely used as an adjunct to psychotherapy in the treatment of depression and anxiety. Recently, the safety and ease of practical use of psilocybin propelled its resurrection and positive preliminary reports on the safety and tolerability of psilocybin for multiples diseases, such as obsessive-compulsive disorder and addiction, have been published. Aims: The main objective of this review is to outline existing scientific information about the effects of Psilocybin-based therapy on patients diagnosed with depression. Methods: Using PubMed as the database, a research was conducted, based on the research words *Psilocybin and *Depression and targeting clinical trials. References of selected articles and review articles were also assessed. Results: A total of 4 articles met the inclusion criteria. 2 articles evaluate psilocybin effects in 32 patients with treatment-resistant depression. The remaining 2 articles evaluate psilocybin effects in 80 patients with cancer-related anxiety and depression. All articles showed that psilocybin produced immediate and substantial improvements in depression, that, ultimately, could sustain up to 6 months. Conclusion: Psilocybin-assisted therapy is a very appealing new possibility in the treatment of depression. However, due to the small populations of the existing trials, future studies are needed to prove this positive association and to fully understand Psilocybin´s mechanisms of action and effects.2020-06-052020-06-05T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfhttps://hdl.handle.net/10216/128706TID:202618277engRui Pedro Leal Andradeinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-29T14:41:59Zoai:repositorio-aberto.up.pt:10216/128706Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T00:07:03.613678Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Psilocybin-assisted therapy and depression - a systematic review
title Psilocybin-assisted therapy and depression - a systematic review
spellingShingle Psilocybin-assisted therapy and depression - a systematic review
Rui Pedro Leal Andrade
Medicina clínica
Clinical medicine
title_short Psilocybin-assisted therapy and depression - a systematic review
title_full Psilocybin-assisted therapy and depression - a systematic review
title_fullStr Psilocybin-assisted therapy and depression - a systematic review
title_full_unstemmed Psilocybin-assisted therapy and depression - a systematic review
title_sort Psilocybin-assisted therapy and depression - a systematic review
author Rui Pedro Leal Andrade
author_facet Rui Pedro Leal Andrade
author_role author
dc.contributor.author.fl_str_mv Rui Pedro Leal Andrade
dc.subject.por.fl_str_mv Medicina clínica
Clinical medicine
topic Medicina clínica
Clinical medicine
description Background: Psilocybin is a naturally occurring serotonin receptor agonist that can be, more commonly, found in the Psilocybe mushrooms. Consumed by indigenous cultures for millenia, Psilocybin, in the 1960s, was marketed in many countries under the trade name Indocybin, and, before its eventual ban, was safely used as an adjunct to psychotherapy in the treatment of depression and anxiety. Recently, the safety and ease of practical use of psilocybin propelled its resurrection and positive preliminary reports on the safety and tolerability of psilocybin for multiples diseases, such as obsessive-compulsive disorder and addiction, have been published. Aims: The main objective of this review is to outline existing scientific information about the effects of Psilocybin-based therapy on patients diagnosed with depression. Methods: Using PubMed as the database, a research was conducted, based on the research words *Psilocybin and *Depression and targeting clinical trials. References of selected articles and review articles were also assessed. Results: A total of 4 articles met the inclusion criteria. 2 articles evaluate psilocybin effects in 32 patients with treatment-resistant depression. The remaining 2 articles evaluate psilocybin effects in 80 patients with cancer-related anxiety and depression. All articles showed that psilocybin produced immediate and substantial improvements in depression, that, ultimately, could sustain up to 6 months. Conclusion: Psilocybin-assisted therapy is a very appealing new possibility in the treatment of depression. However, due to the small populations of the existing trials, future studies are needed to prove this positive association and to fully understand Psilocybin´s mechanisms of action and effects.
publishDate 2020
dc.date.none.fl_str_mv 2020-06-05
2020-06-05T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://hdl.handle.net/10216/128706
TID:202618277
url https://hdl.handle.net/10216/128706
identifier_str_mv TID:202618277
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799135996364718081